Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral BCX7353 for prevention of hereditary angioedema attacks
2017-003966-29Phase 3Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of berotralstat in hereditary angioedema (HAE) (3 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Rate of investigator-confirmed hereditary angioedema attacks during the 24-week treatment period. Started Mar 2018; status: terminated.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2017-003966-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003966-29.